{"pmid":32447736,"title":"Lack of Efficacy of SGLT2-i in Severe Pneumonia Related to Novel Coronavirus (nCoV) Infection: No Little Help from Our Friends.","text":["Lack of Efficacy of SGLT2-i in Severe Pneumonia Related to Novel Coronavirus (nCoV) Infection: No Little Help from Our Friends.","Diabetes Ther","Bossi, Antonio Carlo","Forloni, Franco","Colombelli, Paolo Luigi","32447736"],"journal":"Diabetes Ther","authors":["Bossi, Antonio Carlo","Forloni, Franco","Colombelli, Paolo Luigi"],"date":"2020-05-25T11:00:00Z","year":2020,"_id":"32447736","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1007/s13300-020-00844-8","keywords":["covid-19 related pneumonia","non-diabetic patients","sglt2-inhibitors"],"topics":["Mechanism","Treatment"],"weight":1,"_version_":1667698385920983041,"score":9.490897,"similar":[{"pmid":32358609,"pmcid":"PMC7197558","title":"The COVID-19 outbreak and the angiotensin-converting enzyme 2: too little or too much?","text":["The COVID-19 outbreak and the angiotensin-converting enzyme 2: too little or too much?","Nephrol Dial Transplant","Essig, Marie","Matt, Morgan","Massy, Ziad","32358609"],"journal":"Nephrol Dial Transplant","authors":["Essig, Marie","Matt, Morgan","Massy, Ziad"],"date":"2020-05-03T11:00:00Z","year":2020,"_id":"32358609","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.1093/ndt/gfaa113","topics":["Treatment","Mechanism"],"weight":1,"_version_":1666138495310102529,"score":43.91186},{"pmid":32430461,"title":"Lack of efficacy of hydroxychloroquine in covid-19.","text":["Lack of efficacy of hydroxychloroquine in covid-19.","BMJ","Vinetz, Joseph M","32430461"],"journal":"BMJ","authors":["Vinetz, Joseph M"],"date":"2020-05-21T11:00:00Z","year":2020,"_id":"32430461","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1136/bmj.m2018","link_comment_for":"32409561","e_drugs":["Hydroxychloroquine"],"topics":["General Info"],"weight":1,"_version_":1667342288165011456,"score":41.185406},{"pmid":32340044,"title":"The ACE-2 in COVID-19: Foe or Friend?","text":["The ACE-2 in COVID-19: Foe or Friend?","COVID-19 is a rapidly spreading outbreak globally. Emerging evidence demonstrates that older individuals and people with underlying metabolic conditions of diabetes mellitus, hypertension, and hyperlipidemia are at higher risk of morbidity and mortality. The SARS-CoV-2 infects humans through the angiotensin converting enzyme (ACE-2) receptor. The ACE-2 receptor is a part of the dual system renin-angiotensin-system (RAS) consisting of ACE-Ang-II-AT1R axis and ACE-2-Ang-(1-7)-Mas axis. In metabolic disorders and with increased age, it is known that there is an upregulation of ACE-Ang-II-AT1R axis with a downregulation of ACE-2-Ang-(1-7)-Mas axis. The activated ACE-Ang-II-AT1R axis leads to pro-inflammatory and pro-fibrotic effects in respiratory system, vascular dysfunction, myocardial fibrosis, nephropathy, and insulin secretory defects with increased insulin resistance. On the other hand, the ACE-2-Ang-(1-7)-Mas axis has anti-inflammatory and antifibrotic effects on the respiratory system and anti-inflammatory, antioxidative stress, and protective effects on vascular function, protects against myocardial fibrosis, nephropathy, pancreatitis, and insulin resistance. In effect, the balance between these two axes may determine the prognosis. The already strained ACE-2-Ang-(1-7)-Mas in metabolic disorders is further stressed due to the use of the ACE-2 by the virus for entry, which affects the prognosis in terms of respiratory compromise. Further evidence needs to be gathered on whether modulation of the renin angiotensin system would be advantageous due to upregulation of Mas activation or harmful due to the concomitant ACE-2 receptor upregulation in the acute management of COVID-19.","Horm Metab Res","Dalan, Rinkoo","Bornstein, Stefan R","El-Armouche, Ali","Rodionov, Roman N","Markov, Alexander","Wielockx, Ben","Beuschlein, Felix","Boehm, Bernhard O","32340044"],"abstract":["COVID-19 is a rapidly spreading outbreak globally. Emerging evidence demonstrates that older individuals and people with underlying metabolic conditions of diabetes mellitus, hypertension, and hyperlipidemia are at higher risk of morbidity and mortality. The SARS-CoV-2 infects humans through the angiotensin converting enzyme (ACE-2) receptor. The ACE-2 receptor is a part of the dual system renin-angiotensin-system (RAS) consisting of ACE-Ang-II-AT1R axis and ACE-2-Ang-(1-7)-Mas axis. In metabolic disorders and with increased age, it is known that there is an upregulation of ACE-Ang-II-AT1R axis with a downregulation of ACE-2-Ang-(1-7)-Mas axis. The activated ACE-Ang-II-AT1R axis leads to pro-inflammatory and pro-fibrotic effects in respiratory system, vascular dysfunction, myocardial fibrosis, nephropathy, and insulin secretory defects with increased insulin resistance. On the other hand, the ACE-2-Ang-(1-7)-Mas axis has anti-inflammatory and antifibrotic effects on the respiratory system and anti-inflammatory, antioxidative stress, and protective effects on vascular function, protects against myocardial fibrosis, nephropathy, pancreatitis, and insulin resistance. In effect, the balance between these two axes may determine the prognosis. The already strained ACE-2-Ang-(1-7)-Mas in metabolic disorders is further stressed due to the use of the ACE-2 by the virus for entry, which affects the prognosis in terms of respiratory compromise. Further evidence needs to be gathered on whether modulation of the renin angiotensin system would be advantageous due to upregulation of Mas activation or harmful due to the concomitant ACE-2 receptor upregulation in the acute management of COVID-19."],"journal":"Horm Metab Res","authors":["Dalan, Rinkoo","Bornstein, Stefan R","El-Armouche, Ali","Rodionov, Roman N","Markov, Alexander","Wielockx, Ben","Beuschlein, Felix","Boehm, Bernhard O"],"date":"2020-04-28T11:00:00Z","year":2020,"_id":"32340044","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.1055/a-1155-0501","topics":["Treatment","Mechanism"],"weight":1,"_version_":1666138494297178112,"score":41.117687}]}